Developing Stable Cell Lines for the Production of Vaccine Antigens

Development of Vaccines: From Discovery to Clinical Testing

Volumn , Issue , 2011, Pages 243-259

  Zhong, Xiaotian ^a   Lu, Zhijian ^a   Zollner, Richard ^a   Zhang, Jimin ^a   Braunstein, Emily ^b   Kalyan, Narender ^b   Sidhu, Maninder ^b  

^a PFIZER INC   (United States)

^b Pfizer Vaccine Research Operations and Strategy   (United States)

Author keywords

Key chinese hamster ovary (CHO) technologies protocols, for various purposes with modifications; Stable cell lines, replication defective viral vaccine production complementing cell line; Stable cell lines for vaccine antigen production

Indexed keywords

EID: 84874409214     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118023648.ch9     Document Type: Chapter

References (40)

1. Harrison S, Adamson S, Bonam D, Brodeur S, Charlebois T, Clancy B, Costigan R, Drapeau D, Hamilton M, Hanley K, Kelley B, Knight A, Leonard M, McCarthy M, Oakes P, Sterl K, Switzer M, Walsh R and Foster W. The manufacturing process for recombinant factor IX. Semin. Hematol. 1998;35(2 Suppl 2):4-10.
2. Eriksson RK, et al. The manufacturing process for B-domain deleted recombinant factor VIII. Semin. Hematol. 2001;38(2 Suppl 4):24-31.
3. Soler E and Houdebine LM. Preparation of recombinant vaccines. Biotechnol. Annu. Rev. 2007;13:65-94.
4. Liljeqvist S and Stahl S. Production of recombinant subunit vaccines: Protein immunogens, live delivery systems and nucleic acid vaccines. J. Biotechnol. 1999;73(1):1-33.
5. van Drunen Littel-van den Hurk S, et al. Immunopathology of RSV infection: Prospects for developing vaccines without this complication. Rev. Med. Virol . 2007;17(1):5-34.
6. Du L, et al. Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. Virology 2009;393(1):144-150.
7. Du L, et al. Antigenicity and immunogenicity of SARS-CoV S protein receptorbinding domain stably expressed in CHO cells. Biochem. Biophys. Res. Commun. 2009;384(4):486-490.
8. Du L, et al. The spike protein of SARS-CoV-a target for vaccine and therapeutic development. Nat. Rev. Microbiol . 2009;7(3):226-236.
9. Zhang MY and Dimitrov DS. Novel approaches for identification of broadly cross-reactive HIV-1 neutralizing human monoclonal antibodies and improvement of their potency. Curr. Pharm. Des. 2007;13(2):203-212.
10. Zhang MY, et al. Cross-reactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: Possible role of the prolonged half-life of the immunogen. Vaccine 2009;27(6):857-863.
11. Karlsson Hedestam GB, et al. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat. Rev. Microbiol . 2008;6(2):143-155.
12. Prince GA, et al. Efficacy and safety studies of a recombinant chimeric respiratory syncytial virus FG glycoprotein vaccine in cotton rats. J. Virol . 2000;74(22): 10287-10292.
13. Nallet S, et al. Respiratory syncytial virus subunit vaccine based on a recombinant fusion protein expressed transiently in mammalian cells. Vaccine, 2009;27:6415-6419.
14. Geisse S, et al. Eukaryotic expression systems: A comparison. Protein Expr. Purif . 1996;8(3):271-282.
15. Wurm FM. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat. Biotechnol. 2004;22(11):1393-1398.
16. Liniger M, et al. Use of viral vectors for the development of vaccines. Expert Rev. Vaccines 2007;6(2):255-266.
17. Puck TT, Cieciura SJ, and Robinson A. Genetics of somatic mammalian cells. III. Long-term cultivation of euploid cells from human and animal subjects. J. Exp. Med. 1958;108(6):945-956.
18. Kao FT and Puck TT. Genetics of somatic mammalian cells, VII. Induction and isolation of nutritional mutants in Chinese hamster cells. Proc. Natl. Acad. Sci. USA 1968;60(4):1275-1281.
19. Urlaub G and Chasin LA. Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity. Proc. Natl. Acad. Sci. USA 1980;77(7):4216-4220.
20. Subramani S, Mulligan R, and Berg P. Expression of the mouse dihydrofolate reductase complementary deoxyribonucleic acid in simian virus 40 vectors. Mol. Cell Biol . 1981;1(9):854-864.
21. Kaufman RJ and Sharp PA. Amplification and expression of sequences cotransfected with a modular dihydrofolate reductase complementary dna gene. J. Mol. Biol . 1982;159(4):601-621.
22. McCormick F, et al. Inducible expression of amplified human beta interferon genes in CHO cells. Mol. Cell Biol . 1984;4(1):166-172.
23. Kaufman RJ, et al. Coamplification and coexpression of human tissue-type plasminogen activator and murine dihydrofolate reductase sequences in Chinese hamster ovary cells. Mol. Cell Biol . 1985;5(7):1750-1759.
24. Page MJ. Expression of amplified human beta interferon genes using heavy metal induction in Chinese hamster ovary cells. Gene 1985;37(1-3):139-144.
25. Jun SC, et al. Selection strategies for the establishment of recombinant Chinese hamster ovary cell line with dihydrofolate reductase-mediated gene amplification. Appl. Microbiol. Biotechnol. 2005;69(2):162-169.
26. Israel DI, et al. Expression and characterization of bone morphogenetic protein-2 in Chinese hamster ovary cells. Growth Factors 1992;7(2):139-150.
27. Gandor C, et al. Amplification and expression of recombinant genes in serum-independent Chinese hamster ovary cells. FEBS Lett 1995;377(3):290-294.
28. Sinacore MS, Drapeau D, and Adamson SR. Adaptation of mammalian cells to growth in serum-free media. Mol. Biotechnol. 2000;15(3):249-257.
29. Baum C, et al. An optimized electroporation protocol applicable to a wide range of cell lines. Biotechniques 1994;17(6):1058-1062.
30. Batard P, Jordan M, and Wurm F. Transfer of high copy number plasmid into mammalian cells by calcium phosphate transfection. Gene 2001;270(1-2):61-68.
31. Hodgson CP and Solaiman F. Virosomes: Cationic liposomes enhance retroviral transduction. Nat. Biotechnol. 1996;14(3):339-342.
32. Galbraith DJ, et al. Control of culture environment for improved polyethylenimine-mediated transient production of recombinant monoclonal antibodies by CHO cells. Biotechnol. Prog. 2006;22(3):753-762.
33. Southern PJ and Berg P. Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. J. Mol. Appl. Genet . 1982;1(4):327-341.
34. Mulsant P, et al. Phleomycin resistance as a dominant selectable marker in CHO cells. Somat. Cell Mol. Genet . 1988;14(3):243-252.
35. Gritz L and Davies J. Plasmid-encoded hygromycin B resistance: The sequence of hygromycin B phosphotransferase gene and its expression in Escherichia coli and Saccharomyces cerevisiae. Gene 1983;25(2-3):179-188.
36. de la Luna S and Ortin J. pac gene as efficient dominant marker and reporter gene in mammalian cells. Methods Enzymol. 1992;216:376-385.
37. Simonsen CC and Levinson AD. Isolation and expression of an altered mouse dihydrofolate reductase cDNA. Proc. Natl. Acad. Sci. USA 1983;80(9):2495-2496.
38. Page MT, and Thorp R. The Protein Protocols Handbook. Walker J M (Ed.). Humana Press, Totoma, NJ, 1996, pp. 1117-1118.
39. Page MT and Thorp R. The Protein Protocols Handbook. Walker J M (Ed.). Humana Press, Totowa, NJ 1996, pp. 317-320.
40. Witko et al. Refined methods for propagating vesicular stomatitis virus vectors that are defetctive for a G protein expression. J. Virol. Methods 2010;164:43-50.